Abstract 【Objective】To investigate the efficacy of bevacizumab combined with paclitaxel in the treatment of advanced breast cancer and its effect on patients' immune function. 【Methods】Eighty patients with advanced breast cancer admitted to our hospital were randomly divided into two groups,with 40 patients in each group. The observation group was treated with paclitaxel + bevacizumab,while the control group was treated with paclitaxel alone. The clinical efficacy,serum-related markers [Vascular Endothelial Growth Factor (VEGF),Basic Fibroblast Growth Factor (bF-GF)],tumor markers [Serum Carcinoembryonic Antigen (CEA),Carbohydrate Antigen 125 (CA125)],and immune function indicators (CD3+,CD4+,CD4+/CD8+) level changes and the incidence of adverse reactions in both groups were compared. 【Results】The total remission rate of the observation group was 75.00% (30/40),which was significantly higher than 50.00% (20/40) of the control group. And the difference was statistically significant (P<0.05). After treatment,the levels of VEGF,bF-GF,CEA,and CA125 in both groups decreased compared to before treatment (P<0.05),and the aforementioned indicators in the observation group were lower than those in the control group (P<0.05). After treatment,the levels of CD3+,CD4+,and CD4+/CD8+ in both groups increased compared to before treatment (P<0.05),and the levels of CD3+,CD4+,and CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions in both groups showed no statistical difference (P>0.05). 【Conclusion】The use of bevacizumab combined with paclitaxel chemotherapy in advanced breast cancer can improve the immune function of patients,effectively reduce tumor markers and serum-related factors,and demonstrate good clinical efficacy. The combination treatment does not increase adverse reactions,which is worthy of clinical promotion and application.
TAN Yue,LI Gang,LI Xue-lian, et al. Efficacy of Bevacizumab Combined with Paclitaxel and its Effect on Patients' Immune Function in the Treatment of Advanced Breast Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(8): 1132-1135.
2023, Vol. 40 
